Mesa Laboratories (NASDAQ:MLAB) Issues Quarterly Earnings Results

Mesa Laboratories (NASDAQ:MLAB) announced its earnings results on Monday. The medical instruments supplier reported $2.68 earnings per share for the quarter, reports. The business had revenue of $60.14 million for the quarter. Mesa Laboratories had a return on equity of 22.87% and a net margin of 1.92%.

Here are the key takeaways from Mesa Laboratories’ conference call:

• Revenue returned to organic growth: First-quarter revenue rose 1% to $60.1 million, while adjusted operating income increased 16.5% to $15.0 million, with adjusted margin expanding to 25.6%.
• Core franchises showed growth: Biopharmaceutical Development grew 5% organically, Calibration Solutions grew 7.6%, and trailing-12-month Sterilization and Disinfection Control revenue increased about 5%, despite quarterly delivery delays.
• SDC execution remains a key risk: Sterilization and Disinfection Control revenue declined 3.6% year over year as missed delivery dates increased past-due backlog by approximately $1 million; management characterized this as a reliability issue rather than weak demand but did not provide a recovery timetable.
• Management is prioritizing internal improvements over acquisitions: Mesa repaid $8.7 million of debt, reduced net leverage to 1.85x, and is targeting 1.5x–1.75x by fiscal year-end while reallocating resources toward higher-return businesses.
• Growth initiatives are still developing: A new BPD general manager is rebuilding the commercial organization, and Mesa accelerated development of a next-generation Gyrolab platform targeted for fiscal 2028; full-year fiscal 2027 guidance is deferred until November.

Mesa Laboratories Trading Up 0.7%

MLAB traded up $0.81 on Wednesday, hitting $112.04. 146,852 shares of the company were exchanged, compared to its average volume of 147,223. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.29 and a current ratio of 1.72. The firm has a fifty day simple moving average of $100.34 and a two-hundred day simple moving average of $95.50. The stock has a market capitalization of $627.42 million, a PE ratio of 133.38 and a beta of 0.92. Mesa Laboratories has a 12 month low of $58.83 and a 12 month high of $113.99.

Mesa Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Monday, August 31st will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.6%. The ex-dividend date is Monday, August 31st. Mesa Laboratories’s dividend payout ratio (DPR) is presently 53.33%.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $94.00.

Insider Transactions at Mesa Laboratories

In related news, SVP Brian David Archbold sold 2,516 shares of Mesa Laboratories stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $225,182.00. Following the transaction, the senior vice president directly owned 6,377 shares of the company’s stock, valued at $570,741.50. The trade was a 28.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO John Sakys sold 2,827 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $253,016.50. Following the sale, the chief financial officer owned 19,785 shares of the company’s stock, valued at $1,770,757.50. This represents a 12.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 8,277 shares of company stock worth $770,122. Insiders own 2.80% of the company’s stock.

Hedge Funds Weigh In On Mesa Laboratories

Several hedge funds have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. boosted its holdings in Mesa Laboratories by 5,366.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 322 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Mesa Laboratories during the 4th quarter valued at about $27,000. Kestra Advisory Services LLC purchased a new position in shares of Mesa Laboratories during the fourth quarter valued at about $55,000. BNP Paribas Financial Markets raised its stake in Mesa Laboratories by 115.3% in the second quarter. BNP Paribas Financial Markets now owns 786 shares of the medical instruments supplier’s stock worth $74,000 after buying an additional 421 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Mesa Laboratories by 432.9% in the second quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock worth $79,000 after buying an additional 684 shares during the period. 90.60% of the stock is owned by hedge funds and other institutional investors.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.